Austrianova announces the publication of a peer-reviewed article on the use of implanted Cell-in-a-Box encapsulated cells for the sustained production of the anti-aging protein[...]

Brian Salmons, Austrianova's CEO added "This publication provides the background and future perspectives for our ongoing collaboration with Avaí Bio through our joint venture company, Klothonova.

This press release can be viewed online at: https://www.openpr.com/news/4675770/austrianova-announces-the-publication-of-a-peer-reviewed

Publication: Maintaining Klotho: preventing the body from unwinding

SG Austria/Austrianova (the SG Austria group comprising of Austrianova Singapore, Austrianova Thailand and Anovade UG) (the "Company") announces the publication of a new manuscript in the international, highly esteemed scientific/medical journal "Frontiers in Aging"1. The peer reviewed article describes the use of implanted Cell-in-a-Box encapsulated cells for the continuous production of the anti-aging protein Klotho in patients. Klotho levels are generally diminished in the elderly, as well as in those suffering for a variety of degenerative diseases including neurodegenerative and cardiovascular disease and cancer. The use of Cell-in-a-Box encapsulated cells (which have already been shown safe and effective in human clinical trials, albeit to deliver other therapeutics) may restore Klotho levels to therapeutically beneficial amounts.

"Klotho has often been described as the biological "stitch in time" that prevents the body from unravelling, a metaphor that captures its role in preserving molecular harmony. Through encapsulation technology, continuous delivery of Klotho potentially may finally achieve what transient gene or protein therapies cannot: a stable restoration of youth's physiological balance." said Walter H. Gunzburg, Chairman of SG Austria/Austrianova.

Brian Salmons, Austrianova's CEO added "This publication provides the background and future perspectives for our ongoing collaboration with Avaí Bio through our joint venture company, Klothonova. We are pleased that this high impact Frontiers journal specializing in aging and anti-aging therapies has published what we believe is a milestone publication."

Maintaining Klotho: preventing the body from unwinding. W.H. Gunzburg, P. Pawa, B. Salmons, Frontiers in Aging, vol. 7, October 2026. https://www.frontiersin.org/journals/aging/articles/10.3389/fragi.2026.1913194/full

About Austrianova (SGAustria Pte. Ltd.)

Austrianova (the SG Austria Group), is a biotech company with a global footprint and operations in Singapore, Thailand, and Germany. Austrianova utilizes a novel and proprietary technology for the encapsulation of living mammalian (Cell-in-a-Box®) and bacterial (Bac-in-a-Box®) cells. Cell-in-a-Box® protects the encapsulated cells from rejection by the immune system, allows cells to be easily transported, stored and implanted at specific sites in patients. The technology, which has been proven safe and efficacious in clinical trials carried out in Europe, allows companies to develop any kind of cells as a one-for-all living pharmaceutical. Bac-in-a-Box® is a similar protective device adapted for encapsulation of probiotic bacteria where it has human food and animal feed applications as well as re-balancing the microbiome due to its ability to extend storage under lyophilized conditions and to protect encapsulated bacteria against destruction by stomach acid.

Austrianova now also offers Pep-in-a-Box encapsulation of enzymes, proteins and supplements to pro-tect them from stomach acid digestion as well as GMP4Cells services that include competitively priced Master Cell Bank and Working Cell Bank production and other production services for cell therapy products (such as stem cell therapies and biologics produced from cells e.g., recombinant proteins, exosomes, etc.).

Visit us on social media:
Facebook
Twitter
LinkedIn